438. Deputy Aindrias Moynihan asked the Minister for Health the number of times the Health Products Regulatory Authority detected illegal sales of prescription medications; if they were animal or human medications; where they were coming from, in each of the past 12-months, in tabular form; and if she will make a statement on the matter. [75232/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
465. Deputy Gillian Toole asked the Minister for Health if the HPRA (Health Product Regulatory Authority) warning system will be inspected and upgraded in light of findings from the Food and Drug Administration in the United States where warnings about adverse events relating to Messenger RNA Covid vaccines were not on alerts. [75302/26]
188. Deputy Micheál Carrigy asked the Minister for Health the progress on the changing of the reimbursement process for new medicines. [74517/26]
217. Deputy Barry Heneghan asked the Minister for Health whether the free HRT scheme will be extended to cover hormone replacement therapy for patients with congenital or permanent endocrine conditions, including testosterone replacement for Klinefelter syndrome. [74737/26]
218. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's assessment of dupilumab for eosinophilic oesophagitis; and the expected date of a decision. [74736/26]
219. Deputy Barry Heneghan asked the Minister for Health the action the HSE and HPRA are taking on the current supply shortage of budesonide orodispersible tablets in the State. [74735/26]
220. Deputy Barry Heneghan asked the Minister for Health the current status of the HSE's full health technology assessment of budesonide orodispersible tablets (Jorveza, NCPE HTA ID 24014) for eosinophilic oesophagitis, commissioned on 25 June 2024; the reason no outcome has been published in over two years; and the expected date of a reimbursement decision. [74734/26]
248. Deputy Eoin Hayes asked the Minister for Health if her Department will review the eligibility criteria for approved preventative medication for hereditary angioedema (HAE). [74913/26]
893. Deputy Conor D. McGuinness asked the Minister for Health if the assessment and approval process for belzutifan will be expedited (details supplied). [73594/26]
1018. Deputy Pádraig Rice asked the Minister for Health the current status of a pricing and reimbursement application (details supplied); and the expected date of a decision. [74469/26]
1021. Deputy Pádraig Rice asked the Minister for Health the actions the HSE and Health Products Regulatory Authority are taking regarding a current supply shortage (details supplied). [74468/26]
1023. Deputy Pádraig Rice asked the Minister for Health the current status of a full health technology assessment (details supplied); the reason no outcome has been published in over two years; and the expected date for a reimbursement decision. [74466/26]
739. Deputy David Cullinane asked the Minister for Health the steps she has taken to ensure that eligible patients will have access to a medication (details supplied) since its approval for reimbursement without avoidable capacity delays; whether regional services will be developed to assist in access and ongoing care; if she will outline the way in which patients will be identified and assessed; the way prescription…
791. Deputy Barry Heneghan asked the Minister for Health whether she is aware of delays in accessing a drug (details supplied) for Friedreich’s ataxia due to capacity constraints at the Combined Ataxia Clinic, Tallaght University Hospital; the timeframe for all eligible patients to commence treatment; whether additional resources will be provided; the current clinic waiting times; and measures to ensure timely specia…
580. Deputy Peadar Tóibín asked the Minister for Health if she is aware that the European Commission granted marketing authorisation on 15 July 2026 for jascayd (nerandomilast); if an application for reimbursement has been received by the HSE and/or the National Centre for Pharmacoeconomics (NCPE); the current status of any assessment, pricing negotiations or reimbursement consideration; the anticipated timeline for …
616. Deputy Michael Cahill asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commenced tre…
618. Deputy Pádraig Mac Lochlainn asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the Combined Ataxia Clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commen…
626. Deputy Louis O'Hara asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have commenced treat…
627. Deputy Pádraig O'Sullivan asked the Minister for Health if a company (details supplied) has engaged with her Department, the HSE or the national centre for pharmacoeconomics regarding reimbursement of ojemda (tovorafenib) in Ireland; whether a reimbursement application has been submitted by the company; if so, the status of that application; if not, whether discussions have taken place with the company regarding…
643. Deputy Eoghan Kenny asked the Minister for Health if her Department will consider the inclusion of GLP-1 drugs like Mounjaro for PCOS treatment in the drugs payment scheme, given the expense of the medication and the considerable cost of living issues. [70234/26]
669. Deputy Conor D. McGuinness asked the Minister for Health whether she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing a drug (details supplied) despite its reimbursement from 1 October 2026 due to capacity constraints at the Combined Ataxia Clinic at Tallaght University Hospital; the estimated timeframe within which all eligible patients will have com…
672. Deputy Shay Brennan asked the Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 (details supplied); the estimated timeframe within which all eligible patients will have commenced treatment; if additional resources will be provided to support treatment ini…
675. Deputy Brian Brennan asked the Minister for Health if she will review the fairness of the drug payment scheme threshold, particularly the application of the same monthly cap to widowed/single-person households and to couples or families. [70527/26]
682. Deputy Mary Lou McDonald asked the Minister for Health if there are plans to trial the use of a medication (details supplied) in Ireland in view of the fact his drug is currently being tested in the United States of America for use in preserving fertility for endometriosis patients. [70557/26]
720. Deputy Seán Kyne asked the Minister for Health the current status of the HSE's assessment of dupilumab for eosinophilic oesophagitis; and the expected date of a decision on the use of this medicine. [70680/26]